Literature DB >> 8795132

The use of lamotrigine in juvenile myoclonic epilepsy.

N Buchanan1.   

Abstract

Lamotrigine (LTG) was used in 12 patients with juvenile myoclonic epilepsy (JME) who either had sodium valproate (VPA) side effects or did not wish to take VPA. Five patients are now fully controlled on LTG monotherapy. Side-effects were corrected by VPA withdrawal or reduction except for severe weight gain. In three patients it was not possible to withdraw VPA due to the re-emergence of myoclonus, suggesting LTG-VPA synergism. Two patients had successful pregnancies whilst taking LTG. Lamotrigine is a useful alternative in the management of JME.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8795132     DOI: 10.1016/s1059-1311(96)80110-5

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  13 in total

1.  Primary Generalized Epilepsies.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-11       Impact factor: 3.598

Review 2.  Molecular targets versus models for new antiepileptic drug discovery.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-01       Impact factor: 3.045

Review 3.  Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.

Authors:  Anna Serafini; Elizabeth Gerard; Pierre Genton; Arielle Crespel; Philippe Gelisse
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

Review 4.  Safety review of adult clinical trial experience with lamotrigine.

Authors:  J Messenheimer; E L Mullens; L Giorgi; F Young
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

Review 5.  Treatment of typical absence seizures and related epileptic syndromes.

Authors:  C P Panayiotopoulos
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

6.  High-dose versus low-dose valproate for the treatment of juvenile myoclonic epilepsy: Going from low to high.

Authors:  Laura E Hernández-Vanegas; Aurelio Jara-Prado; Adriana Ochoa; Nayelli Rodríguez Y Rodríguez; Reyna M Durón; Daniel Crail-Meléndez; Ma Elisa Alonso; Antonio V Delgado-Escueta; Iris E Martínez-Juárez
Journal:  Epilepsy Behav       Date:  2016-06-11       Impact factor: 2.937

Review 7.  Juvenile myoclonic epilepsy: epidemiology, pathophysiology, and management.

Authors:  Timothy E Welty
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 8.  Newer anticonvulsants: comparative review of drug interactions and adverse effects.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 9.  Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine.

Authors:  Linda Steinbaugh; Jerzy P Szaflarski
Journal:  Drug Des Devel Ther       Date:  2010-11-18       Impact factor: 4.162

10.  Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy.

Authors:  Stéphane Auvin
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.